Background Adjunctive newer antiseizure medications (ASMs) are being used in patients
with treatment-resistant focal-onset seizures (FOS). An updated network meta-analysis …

Viral infection in the central nervous system (CNS) is a common cause of seizures and
epilepsy. Acute symptomatic seizures can occur in the context of almost all types of acute …

Objective Perampanel (PER) has been shown to be effective as an adjunctive therapy for
controlling refractory focal-onset seizures (FOS). However, the information as early add-on …

Modern pharmacotherapy for epilepsy consists of orderly, sequential drug trials, in which
antiepileptic drugs (AEDs) are chosen under the concept of individual patient-oriented (or …

Objective The management of pregnant women with epilepsy (WWE) treated with
antiepileptic drugs (AEDs) polytherapy poses a great challenge. The purpose of this study …

Background: Combination therapy with antiseizure medications (ASMs) is a rational strategy
if monotherapy cannot effectively control seizures, thereby aiming to improve tolerance and …

Background: Malformation of cortical development (MCD) is one of the most common
causes of pharmacoresistant epilepsy. Improving the knowledge of antiseizure medications …

Valproic acid (VPA) has long been the most widely used antiepileptic drug (AED) for the
treatment of epilepsy, bipolar psychiatric disorders, and migraine. However, long-term VPA …

Background Perampanel (PER) is an effective adjunctive therapy for controlling focal-onset
seizures (FOS), but few studies have examined its effects as an early add-on for the …

Perampanel is a novel antiepileptic drug, which antagonises AMPA (alpha-amino-3-hydroxy-
5-methyl-4-isoxazolepropionic acid) glutamate receptor. We describe perampanel as an …